<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18699" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bullous Pemphigoid</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Baigrie</surname>
            <given-names>Dana</given-names>
          </name>
          <aff>Campbell University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nookala</surname>
            <given-names>Vinod</given-names>
          </name>
          <aff>UPMC Pinnacle</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dana Baigrie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vinod Nookala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18699.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder, representing 80% of subepidermal immunobullous cases. Bullous pemphigoid most commonly affects elderly patients between the ages of 60 to 80 years. This activity reviews the etiology, presentation, evaluation, and management of bullous pemphigoid and reviews the interprofessional team's role in evaluating, diagnosing, and managing the condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology of bullous pemphigoid.</p></list-item><list-item><p>Describe the pathophysiology of bullous pemphigoid.</p></list-item><list-item><p>Summarize the management options for bullous pemphigoid</p></list-item><list-item><p>Outline possible interprofessional team strategies for improving care coordination and communication to advance the evaluation and treatment of bullous pemphigoid and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18699&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18699">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18699.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering&#x000a0;disorder, representing 80% of subepidermal&#x000a0;immunobullous cases.<xref ref-type="bibr" rid="article-18699.r1">[1]</xref>&#x000a0;Bullous pemphigoid most commonly affects elderly patients between the ages of 60 to 80 years. While the clinical presentation of bullous pemphigoid is broad, the immunobullous skin disorder characteristically presents with tense&#x000a0;bullae and intense generalized pruritus. In atypical cases, bullous lesions may be absent, and these cases require a high degree of clinical suspicion. A biopsy for hematoxylin and eosin staining will&#x000a0;show a subepidermal split with eosinophils, and direct immunofluorescence will highlight the autoantibodies against the basement membrane zone. ELISA testing is also useful in diagnosing bullous pemphigoid. Treatment depends on the severity of the disease; however, standard therapies involve topical or systemic immunosuppressive agents.<xref ref-type="bibr" rid="article-18699.r2">[2]</xref>&#x000a0;Prognosis varies, and long-term monitoring is often required.</p>
      </sec>
      <sec id="article-18699.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>While most bullous pemphigoid cases are due to autoantibodies against proteins arranged at the dermal-epidermal junction, some cases of bullous pemphigoid are&#x000a0;caused by systemic medications. Drug-induced bullous pemphigoid occurs up to three months after&#x000a0;medication initiation and is typically noted in a younger subset of patients. The drugs reported in the literature to cause bullous pemphigoid-like eruptions to include&#x000a0;diuretics such as furosemide and spironolactone, NSAIDs, amoxicillin, PD-1/PD-L1 inhibitors, gliptins, and TNF-alpha inhibitors.<xref ref-type="bibr" rid="article-18699.r3">[3]</xref></p>
      </sec>
      <sec id="article-18699.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>As mentioned above, BP affects individuals older than 60 years of age.<xref ref-type="bibr" rid="article-18699.r4">[4]</xref> Annual incidence is 6 to 13 new cases per million people in the United States, while it affects 12 to 13 per million in Central Europe. It has an equal incidence in both males and females and has no racial bias. This disease may present in childhood, but this is rare. Specific HLA class II alleles can be found in BP patients, including the allele DQB1*0301 in White race patients, and alleles DRB1*04, DRB1*1101, and DQB1*0302 in Japanese patients.<xref ref-type="bibr" rid="article-18699.r4">[4]</xref><xref ref-type="bibr" rid="article-18699.r5">[5]</xref></p>
      </sec>
      <sec id="article-18699.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>There are 2 main components to the pathophysiology of BP: immunologic and inflammatory. The immunologic elements comprise autoantibodies against 2 parts of the basal keratinocyte hemidesmosomal proteins BP antigen 230 (BPAG1) and BP antigen 180 (BPAG2 or type XVII collagen).<xref ref-type="bibr" rid="article-18699.r6">[6]</xref>&#x000a0;These antigens play an essential part in the adhesion complexes that promote epithelial-stromal adhesion.&#x000a0;When autoantibodies bind to their target antigen, the inflammatory component follows, activating complement and mast cells. This causes neutrophils and eosinophils to release various inflammatory cells resulting in the release&#x000a0;of proteolytic enzymes that damage the dermal-epidermal junction.<xref ref-type="bibr" rid="article-18699.r7">[7]</xref></p>
      </sec>
      <sec id="article-18699.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathology will reveal a subepidermal split with a superficial perivascular inflammatory infiltrate and&#x000a0;numerous&#x000a0;eosinophils. Spongiosis and superficial papillary dermal infiltrate of eosinophils without vesiculation are characteristic features of urticarial&#x000a0;lesions and may indicate the dermatopathologist to a diagnosis of urticarial or pre-bullous pemphigoid.<xref ref-type="bibr" rid="article-18699.r8">[8]</xref>&#x000a0;In these cases, direct immunofluorescence studies are imperative.</p>
        <p>Direct immunofluorescence involves directly detecting tissue bound autoantibodies and is the gold standard of evaluation in autoimmune blistering diseases. It is imperative to biopsy the site of the skin lesion to&#x000a0;get&#x000a0;direct immunofluorescence.&#x000a0;At least 2 punch biopsies should be obtained at the time of evaluation: one to send for hematoxylin and eosin staining, and the other&#x000a0;is perilesional, uninvolved skin for direct immunofluorescence. DIF pattern for bullous pemphigoid will&#x000a0;show&#x000a0;deposition of C3 and&#x000a0;IgG&#x000a0;in a linear homogeneous pattern at the basement membrane zone.<xref ref-type="bibr" rid="article-18699.r9">[9]</xref>&#x000a0;In the early stages of this skin disease, only C3 may be present.<xref ref-type="bibr" rid="article-18699.r10">[10]</xref> A salt-split skin immunofluorescence study may be done&#x000a0;where the&#x000a0;patient serum is applied on the salt-split skin, which splits the skin at the level of the lamina lucida. Bullous pemphigoid immunoreactants will localize to the epidermal side of the preparation, versus epidermolysis bullosa acquisita, which localizes to the dermal side.<xref ref-type="bibr" rid="article-18699.r11">[11]</xref><xref ref-type="bibr" rid="article-18699.r12">[12]</xref></p>
      </sec>
      <sec id="article-18699.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In the prodromal phase, patients may experience moderate-to-severe pruritus alone or associated with urticarial, papular lesions.<xref ref-type="bibr" rid="article-18699.r13">[13]</xref>&#x000a0;This later evolves to bullae in weeks to months, typically present in the axillae, on the flexor surface of the forearms, medial thighs, trunk, and abdomen. Approximately 20% of patients will have neither bullae nor erosions at the time of presentation.<xref ref-type="bibr" rid="article-18699.r14">[14]</xref>&#x000a0;Constitutional symptoms are uncommon, except in widespread, severe disease. The bullous phase characteristically presents with vesicles and bullae on a background of normal or erythematous skin. The blisters are tense, up to 1 to 4 centimeters in diameter, and sometimes hemorrhagic. They typically contain clear fluid and may persist for several days before leaving erosions and crusts. Unlike pemphigus vulgaris, the Nikolsky sign is negative in typical cases of bullous pemphigoid (see <bold>Image.</bold> Bullous Pemphigoid).</p>
        <p>Childhood cases are rare. However, there have been cases of infantile bullous pemphigoid, which presents in an acral distribution in the first year of life. <xref ref-type="bibr" rid="article-18699.r15">[15]</xref><xref ref-type="bibr" rid="article-18699.r16">[16]</xref>&#x000a0;The other variant of bullous pemphigoid of childhood are&#x000a0;cases localized to the vulva.<xref ref-type="bibr" rid="article-18699.r17">[17]</xref>&#x000a0;&#x000a0;These cases need to be distinguished from other disorders due to the rarity of the former. Therefore, direct immunofluorescence may be necessary. In some childhood cases, IgA antibodies against the NC16A domain of BP180 have been noted.<xref ref-type="bibr" rid="article-18699.r18">[18]</xref>&#x000a0;It is also reported that the infancy subtype is not related to a maternofetal transfer of autoantibodies.<xref ref-type="bibr" rid="article-18699.r19">[19]</xref></p>
        <p>Researchers debate whether bullous pemphigoid is associated with internal malignancy. However, most believe this association is due to the older age of the patient. A recent study found no increased risk for concurrent or subsequent malignancies in patients with bullous pemphigoid.<xref ref-type="bibr" rid="article-18699.r20">[20]</xref></p>
      </sec>
      <sec id="article-18699.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosis of the bullous pemphigoid relies on the clinical scenario and laboratory tests. Histology with direct and indirect immunofluorescence studies aid in diagnosis.</p>
        <p>Histology will show&#x000a0;a subepidermal split with a superficial perivascular inflammatory infiltrate and&#x000a0;numerous&#x000a0;eosinophils. Spongiosis and superficial papillary dermal infiltrate of eosinophils without vesiculation&#x000a0;characterize urticarial&#x000a0;lesions and may provide a clue to the dermatopathologist&#x000a0;for diagnosing&#x000a0;urticarial or pre-bullous pemphigoid.<xref ref-type="bibr" rid="article-18699.r8">[8]</xref>&#x000a0;Direct immunofluorescence studies are necessary.</p>
        <p>Direct immunofluorescence involves directly detecting tissue bound autoantibodies and is the gold standard of evaluation in autoimmune blistering diseases. It is&#x000a0;necessary to biopsy the site of the skin lesion&#x000a0;for&#x000a0;direct immunofluorescence.&#x000a0;At least two punch biopsies should be obtained at the time of evaluation: one for hematoxylin and eosin staining&#x000a0;and another&#x000a0;using perilesional, uninvolved skin for direct immunofluorescence. DIF pattern for bullous pemphigoid&#x000a0;demonstrates deposition of C3 and&#x000a0;IgG&#x000a0;in a linear homogeneous pattern at the basement membrane zone.<xref ref-type="bibr" rid="article-18699.r9">[9]</xref>&#x000a0;In the early stages of skin disease, only C3 may be present.<xref ref-type="bibr" rid="article-18699.r10">[10]</xref>&#x000a0;A salt-split skin immunofluorescence study&#x000a0;is an option, where the&#x000a0;patient serum is applied on salt-split skin, which splits the skin at the level of the lamina lucida. Bullous pemphigoid immunoreactants will localize to the epidermal side of the preparation, versus epidermolysis bullosa acquisita, which localizes to the dermal side.<xref ref-type="bibr" rid="article-18699.r11">[11]</xref><xref ref-type="bibr" rid="article-18699.r12">[12]</xref></p>
        <p>ELISA testing to detect antibodies to the NC16A domain of BP180, also known as BPAG2, is available and has a sensitivity of 89% and specificity of 98%. Autoantibodies to BP180 and BP230 may be identified in normal subjects without bullous pemphigoid, but they will not bind to the NC16A domain.&#x000a0;<xref ref-type="bibr" rid="article-18699.r21">[21]</xref><xref ref-type="bibr" rid="article-18699.r22">[22]</xref></p>
        <p>The clinical predictors of bullous pemphigoid were described in a report from the French Bullous Study Group in 1998. They suggested that patients with a subepidermal blistering disorder associated with linear deposits of&#x000a0;IgG&#x000a0;or C3 along the epidermal basement membrane without skin&#x000a0;atrophy, mucosal or head, and neck involvement, and older than 70 years strongly supports&#x000a0;a diagnosis&#x000a0;of BP. Their reports stated three out of four diagnostic criteria have a sensitivity of 90% and specificity of 83%.<xref ref-type="bibr" rid="article-18699.r1">[1]</xref></p>
      </sec>
      <sec id="article-18699.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The mainstay of treatment for bullous pemphigoid&#x000a0;is systemic corticosteroids, but treatment ultimately depends on comorbidities and the extent of the disease. For localized disease, less than 20% body surface area in an elderly patient,&#x000a0;super-potent topical steroids such as clobetasol may be used.<xref ref-type="bibr" rid="article-18699.r23">[23]</xref>&#x000a0;Topical steroids combined with nicotinamide plus tetracycline, minocycline, or doxycycline have shown success in multiple cases.<xref ref-type="bibr" rid="article-18699.r24">[24]</xref></p>
        <p>For extensive disease, systemic prednisone at a dose of 0.5&#x000a0;to 1.0mg/kg per day is recommended. This dose of systemic corticosteroids controls the disease within approximately two weeks and&#x000a0;can be slowly tapered&#x000a0;over six to nine months or longer. This treatment regimen is limited by patient age, comorbidities, and side effects. Potent topical corticosteroids can control generalized BP with fewer systemic side effects.<xref ref-type="bibr" rid="article-18699.r25">[25]</xref></p>
        <p>Immunosuppressive&#x000a0;therapy is used when steroids do not control the disease or if patients have contraindications for systemic corticosteroid treatments. Alternative agents include azathioprine,&#x000a0;mycophenolate&#x000a0;mofetil, methotrexate,&#x000a0;chlorambucil, and cyclophosphamide.&#x000a0;If all other treatments fail, IVIG, anti-CD20 (rituximab), or omalizumab can be used&#x000a0;for treatment-resistant cases.<xref ref-type="bibr" rid="article-18699.r25">[25]</xref></p>
        <p>Serum&#x000a0;IgG autoantibodies levels to BP180 have been shown to correlate with disease severity in several ELISA-based studies. Also, a high BP180-NC16A ELISA score and positive direct immunofluorescence at the end of therapy show possible relapse.<xref ref-type="bibr" rid="article-18699.r14">[14]</xref><xref ref-type="bibr" rid="article-18699.r26">[26]</xref></p>
      </sec>
      <sec id="article-18699.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The presence of bullae can be a nonspecific&#x000a0;finding and resemble various dermatoses depending on the timing in the clinical course. Drug reactions, contact dermatitis, urticarial dermatoses, arthropod reactions, other autoimmune bullous disorders such as pemphigus vulgaris, and scabies.&#x000a0;Bullae&#x000a0;can also form secondary to allergic contact dermatitis, Stevens-Johnson syndrome, dyshidrotic&#x000a0;eczema,&#x000a0;pseudoporphyria, or porphyria&#x000a0;cutanea&#x000a0;tarda. If bullae&#x000a0;are identified&#x000a0;in childhood,&#x000a0;bullous impetigo, epidermolysis bullosa, and bullous variants of mastocytosis should be considered&#x000a0;in the differential.<xref ref-type="bibr" rid="article-18699.r14">[14]</xref></p>
        <p>Histopathology, direct and indirect immunofluorescence studies, salt-split skin, and ELISA testing may be necessary if the diagnosis of bullous pemphigoid is questioned.</p>
      </sec>
      <sec id="article-18699.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Bullous pemphigoid typically resolves spontaneously in a few months but can remain for up to 5 years. Treatment, as outlined above, can provide symptomatic relief of pain and itching.<xref ref-type="bibr" rid="article-18699.r27">[27]</xref></p>
      </sec>
      <sec id="article-18699.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Morbidity and mortality of bullous pemphigoid can include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Staphylococcal and streptococcal skin infections and sepsis</p>
          </list-item>
          <list-item>
            <p>Viral infections, including herpes simplex or varicella-zoster</p>
          </list-item>
          <list-item>
            <p>Adverse effects of treatment</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18699.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>This disease can render the patient's skin fragile and susceptible to microbial invasion. Patients need to avoid trauma to their skin. Skin hygiene is a crucial component of preventing complications, and patients need to recognize both complications and adverse events from treatment so they can report these to their clinician. They also need to understand the gravity of the condition.</p>
      </sec>
      <sec id="article-18699.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Most general practitioners, nurse practitioners, and primary care providers may not be familiar with BP. This is a serious skin disorder with a very&#x000a0;high morbidity and mortality rate. When patients present with large bullae, it is important to seek a dermatology consultation. The sooner the disorder is treated, the better the prognosis.</p>
        <p>Bullous pemphigoid is typically a chronic disease with unpredictable exacerbations, with up to 30% of affected patients relapsing within the first year. When treatment is discontinued, up to 50% of patients may relapse within the first three months of discontinuation. The mortality rate is increased in bullous pemphigoid due to the elderly population being affected, with a death rate of approximately 10% to 40%.<xref ref-type="bibr" rid="article-18699.r26">[26]</xref></p>
      </sec>
      <sec id="article-18699.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18699&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18699">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/bullous-pemphigoid/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18699">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18699/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18699">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-18699.s16">
        <fig id="article-18699.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Bullous Pemphigoid <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pemphigoid" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-18699.s17">
        <title>References</title>
        <ref id="article-18699.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaillant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Joly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Prost</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Labeille</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bedane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arbeille</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thomine</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lok</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roujeau</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group.</article-title>
            <source>Arch Dermatol</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>134</volume>
            <issue>9</issue>
            <fpage>1075</fpage>
            <page-range>1075-80</page-range>
            <pub-id pub-id-type="pmid">9762017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roujeau</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Benichou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Picard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dreno</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Delaporte</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vaillant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>D'Incan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plantin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bedane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>P</given-names>
              </name>
              <collab>Bullous Diseases French Study Group</collab>
            </person-group>
            <article-title>A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Jan</month>
            <day>31</day>
            <volume>346</volume>
            <issue>5</issue>
            <fpage>321</fpage>
            <page-range>321-7</page-range>
            <pub-id pub-id-type="pmid">11821508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stavropoulos</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Soura</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Antoniou</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced pemphigoid: a review of the literature.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>1133</fpage>
            <page-range>1133-40</page-range>
            <pub-id pub-id-type="pmid">24404939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korman</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Bullous pemphigoid.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1987</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5 Pt 1</issue>
            <fpage>907</fpage>
            <page-range>907-24</page-range>
            <pub-id pub-id-type="pmid">3294944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thivolet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barthelemy</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Bullous pemphigoid.</article-title>
            <source>Semin Dermatol</source>
            <year>1988</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-103</page-range>
            <pub-id pub-id-type="pmid">3153440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giudice</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180.</article-title>
            <source>J Invest Dermatol</source>
            <year>1992</year>
            <month>Sep</month>
            <volume>99</volume>
            <issue>3</issue>
            <fpage>243</fpage>
            <page-range>243-50</page-range>
            <pub-id pub-id-type="pmid">1324962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanley</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Klaus-Kovtun</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Roop</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies.</article-title>
            <source>J Clin Invest</source>
            <year>1988</year>
            <month>Dec</month>
            <volume>82</volume>
            <issue>6</issue>
            <fpage>1864</fpage>
            <page-range>1864-70</page-range>
            <pub-id pub-id-type="pmid">2461961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishioka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Katayama</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sarashi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kubo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sano</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Eosinophilic spongiosis in bullous pemphigoid.</article-title>
            <source>Arch Dermatol</source>
            <year>1984</year>
            <month>Sep</month>
            <volume>120</volume>
            <issue>9</issue>
            <fpage>1166</fpage>
            <page-range>1166-8</page-range>
            <pub-id pub-id-type="pmid">6383222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weigand</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Direct immunofluorescence in bullous pemphigoid: effects of extent and location of lesions.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>437</fpage>
            <page-range>437-40</page-range>
            <pub-id pub-id-type="pmid">2645321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mutasim</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>BB</given-names>
              </name>
            </person-group>
            <article-title>Immunofluorescence in dermatology.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>803</fpage>
            <page-range>803-22; quiz 822-4</page-range>
            <pub-id pub-id-type="pmid">11712024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazarova</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yancey</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Reactivity of autoantibodies from patients with defined subepidermal bullous diseases against 1 mol/L salt-split skin. Specificity, sensitivity, and practical considerations.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>3 Pt 1</issue>
            <fpage>398</fpage>
            <page-range>398-403</page-range>
            <pub-id pub-id-type="pmid">8784276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnadas</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gelpi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Curell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Moragas</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Alomar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Repeat direct immunofluorescence (DIF) test, using, 1 M NaCl treated skin, in the subepidermal autoimmune bullous diseases that contain IgG at the dermal epidermal junction.</article-title>
            <source>J Cutan Pathol</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-41</page-range>
            <pub-id pub-id-type="pmid">10189243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alonso-Llamazares</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Oursler</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Calobrisi</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Bullous pemphigoid presenting as generalized pruritus: observations in six patients.</article-title>
            <source>Int J Dermatol</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>7</issue>
            <fpage>508</fpage>
            <page-range>508-14</page-range>
            <pub-id pub-id-type="pmid">9679691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Zenzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Della Torre</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zambruno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Borradori</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Bullous pemphigoid: from the clinic to the bench.</article-title>
            <source>Clin Dermatol</source>
            <year>2012</year>
            <season>Jan-Feb</season>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-16</page-range>
            <pub-id pub-id-type="pmid">22137222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waisbourd-Zinman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ben-Amitai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Feinmesser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mimouni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adir-Shani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zlotkin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zvulunov</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bullous pemphigoid in infancy: Clinical and epidemiologic characteristics.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-8</page-range>
            <pub-id pub-id-type="pmid">17945382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petronius</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Bullous pemphigoid in two young infants.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2002</year>
            <season>Mar-Apr</season>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-21</page-range>
            <pub-id pub-id-type="pmid">11994172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fisler</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Saeb</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>McKee</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Childhood bullous pemphigoid: a clinicopathologic study and review of the literature.</article-title>
            <source>Am J Dermatopathol</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-9</page-range>
            <pub-id pub-id-type="pmid">12775979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinez-De Pablo</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Ense&#x000f1;at</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vicente</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilaberte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mascar&#x000f3;</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Childhood bullous pemphigoid: clinical and immunological findings in a series of 4 cases.</article-title>
            <source>Arch Dermatol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>143</volume>
            <issue>2</issue>
            <fpage>215</fpage>
            <page-range>215-20</page-range>
            <pub-id pub-id-type="pmid">17310001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiav&#x000e9;rini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hamel-Teillac</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Prost</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Absence of anti-BP180 antibodies in mothers of infants with bullous pemphigoid.</article-title>
            <source>Br J Dermatol</source>
            <year>2006</year>
            <month>May</month>
            <volume>154</volume>
            <issue>5</issue>
            <fpage>839</fpage>
            <page-range>839-43</page-range>
            <pub-id pub-id-type="pmid">16634883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ong</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goldacre</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goldacre</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999-2011.</article-title>
            <source>Arch Dermatol Res</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>306</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-80</page-range>
            <pub-id pub-id-type="pmid">23912480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakuma-Oyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Oyama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhogal</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid.</article-title>
            <source>Br J Dermatol</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>151</volume>
            <issue>1</issue>
            <fpage>126</fpage>
            <page-range>126-31</page-range>
            <pub-id pub-id-type="pmid">15270881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mariotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grosso</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Terracina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruffelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cordiali-Fei</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sera</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zambruno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mastrogiacomo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Zenzo</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients.</article-title>
            <source>Br J Dermatol</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>151</volume>
            <issue>5</issue>
            <fpage>1004</fpage>
            <page-range>1004-10</page-range>
            <pub-id pub-id-type="pmid">15541078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roujeau</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lok</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bastuji-Garin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mhalla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Enginger</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>High risk of death in elderly patients with extensive bullous pemphigoid.</article-title>
            <source>Arch Dermatol</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>134</volume>
            <issue>4</issue>
            <fpage>465</fpage>
            <page-range>465-9</page-range>
            <pub-id pub-id-type="pmid">9554299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Wojnarowska</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kirtschig</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Godec</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chalmers</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Childs</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Whitham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nunn</surname>
                <given-names>AJ</given-names>
              </name>
              <collab>UK Dermatology Clinical Trials Network BLISTER Study Group</collab>
            </person-group>
            <article-title>Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Apr</month>
            <day>22</day>
            <volume>389</volume>
            <issue>10079</issue>
            <fpage>1630</fpage>
            <page-range>1630-1638</page-range>
            <pub-id pub-id-type="pmid">28279484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilgi&#x000e7; Temel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bassorgun</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Akman-Karaka&#x0015f;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alpsoy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Uzun</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments.</article-title>
            <source>Case Rep Dermatol</source>
            <year>2017</year>
            <season>Jan-Apr</season>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-44</page-range>
            <pub-id pub-id-type="pmid">28413387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fichel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barbe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Joly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bedane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vabres</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Truchetet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Aubin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jegou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grange</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Antonicelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study.</article-title>
            <source>JAMA Dermatol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>150</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-33</page-range>
            <pub-id pub-id-type="pmid">24226428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18699.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pezzolo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Naldi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of major chronic inflammatory immune-related skin diseases in 2019.</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-166</page-range>
            <pub-id pub-id-type="pmid">31962053</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
